Scotland legalized the home use of misoprostol in the year 2017 for the purpose of EMA. Women up to 9+6 weeks’ gestation can now self-administer the drug at home.
This study was conducted with the purpose to evaluate the impact of this change on the uptake and success rate of EMA, and on the provision of effective contraception on discharge.
The main outcome measures of importance were uptake of EMA, the success of EMA, and the provision of LARC to women undergoing EMA. There was a statistically significant increase in the uptake of EMA from 698/1075 women in the first study period to 823/1146 in the second study period. There was no statistically significant difference in the success rate of EMA.
The study concluded through its findings that the self-administration of misoprostol at home increased uptake of EMA. This use had no effect on the high success rate that was previously seen with the clinic administration of misoprostol. The reduced number of visits associated with home use of misoprostol has not affected the provision of effective contraception to women.